Skip to main content

Genomic Solutions--Er, Harvard Bioscience--Nabs Hybridization Patent

NEW YORK, Dec. 2 - A Harvard Bioscience subsidiary has won a patent for a hybridization technology that currently features in a pair of marketed devices.

 

The patent, announced last week, is the second one for this particular technology, developed by Harvard Bioscience's Genomic Solutions unit, Harvard said.

 

US Patent No. 6,432,696, entitled "Thermal and Fluidic Cycling Device for Nucleic Acid Hybridization," describes "a system that automates the processing of DNA and protein microarrays," according to Harvard Bioscience, which bought Genomic Solutions in October. The technology has already enjoyed wide market exposure: Genomic Solutions' GeneTAC Hybstation and GeneTAC Hyb4 "rely" on the technology described in both patents.

 

"Hybridization is a key step in any microarray experiment but one that can introduce unwanted variability," according to John D'Errico, Genomic Solutions' global marketing manager for genomics. The automation of the Hybstation and Hyb4 "eliminate a great deal of human error" from microarray experiments, he said. "We believe this reduces variability and gives researchers better data."

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.